CLINICAL CORE

马约阿尔茨海默病研究中心临床核心的总体目标是通过 招募和仔细诊断患者和对照，各种临床痴呆症的项目， 正在马约诊所罗切斯特和杰克逊维尔进行。临床核心的具体目标是： 1.招募和随访AD退行性疾病谱的受试者，特别关注早期疾病 (MCI); 2.招募AD退行性疾病谱的非裔美国人受试者，特别关注早期 疾病（MCI）; 3.招募并随访非AD痴呆受试者，例如，额颞叶痴呆 路易体、皮质基底节变性; 4.获得对照受试者、MCI和痴呆患者（AD、额颞叶痴呆和Lewy痴呆）的DMA 身体痴呆症），以支持ADRC相关的遗传项目，包括项目2和3;以及 5.为神经病理学核心和ADRC相关项目提供需要临床- 病理相关性 在过去的资助周期中，临床核心在招募和留住受试者方面非常成功。的 Core在几个领域也非常有成效，包括轻度认知障碍的成像， 阿尔茨海默病和非阿尔茨海默痴呆症。内核还大量参与了 额颞叶变性的进展，作为一些关键的家庭，在PGRN突变， 基因最初在临床核心中招募和评估。 对于目前的提案，我们打算继续招募正常的志愿者，包括白人和非洲人 美国人我们还将招募轻度认知障碍、阿尔茨海默病、路易体的患者 痴呆、额颞叶变性和皮质基底节变性。我们所有的科目都将是 根据NACC规定的统一数据集的标准进行表征。 相关性（参见说明）： 临床核心是马约ADRC的核心。核心招募、刻画和追随一个庞大的 正常对照受试者以及轻度认知障碍和各种痴呆患者的数量， 他们是ADRC支持的各种研究项目的参与者。

The overall goal of the Mayo Alzheimer Disease Research Center Clinical Core is to support, through the recruitment and careful diagnosis of patients and controls, the various projects on clinical dementia that are ongoing at the Mayo Clinic Rochester and Jacksonville. The specific aims of the Clinical Core are to: 1. Recruit and follow subjects on the AD degenerative spectrum with a particular focus on early disease (MCI); 2. Recruit African-Americansubjects on the AD degenerative spectrum with special focus on early disease (MCI); 3. Recruit and follow subjects with non-AD dementia, e.g., frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration; 4. Obtain DMA on control subjects, MCI and dementia patients (AD, frontotemporal dementia and Lewy Body Dementia) in order to support ADRC related genetic projects including Projects 2 and 3; and 5. Supply subjects for the Neuropathology Core and ADRC related projects that require clinical- pathological correlation. In the past grant cycle, the Clinical Core has been very successful in recruiting and retaining subjects. The Core has also been very productive in several areas including in imaging in mild cognitive impairment, Alzheimer disease and the non-Alzheimer Dementias. The Core was also heavily involved in the genetic advances in frontotemporal lobar degeneration, as some of the pivotal families the mutations in the PGRN gene were initially recruited and evaluated in the Clinical Core. For the current proposal, we intend to continue to recruit normal volunteers including both whites and African Americans. We will also recruit patients with mild cognitive impairment, Alzheimer disease, Lewy body dementia, frontotemporal lobar degeneration and corticobasal degeneration. All of our subjects will be characterized according to the criteria of the Uniform Data Set specified by the NACC. RELEVANCE (Seeinstructions): The Clinical Core is the centerpiece of the Mayo ADRC. The Core recruits, characterizes and follows a large number of normal control subjects as well as patients with mild cognitive impairment and various dementias, who then are the participants in the various research projects supported by the ADRC.